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(57) ABSTRACT 
Amethod is provided for reducing or preventing bacterioph 
age attack on bacteria used in a cheese making process. The 
method includes (a) treating a blocker peptide precursor 
With a protease enZyme that hydrolyzes the precursor to 
produce blocker peptides; (b) collecting the blocker peptides 
so produced; (c) formulating a starter media With the blocker 
peptides; (d) groWing bulk cultures of cheese making bac 
teria in the inoculated starter media; and (e) adding bacteria 
groWn in the inoculated starter media to a fermentation 
medium for producing cheese. The present invention also 
includes a method of making cheese and cheese produced by 
the method. 
17 Claims, 2 Drawing Sheets 
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CHEESE MAKING WITH BACTERIOPHAGE 
RESISTANT BACTERIA 
TECHNICAL FIELD 
The present invention relates generally to the art of cheese 
making and, more particularly, to a method of improving the 
productivity of the cheese making process and the quality of 
a cheese product by preventing bacteriophage attack on 
bacteria used in the cheese making process. 
BACKGROUND OF THE INVENTION 
Cheese is a milk product that is generally rich in ?avor 
and contains many high-quality nutrients. There are a great 
many varieties of cheese but all are produced in a similar 
manner. First, raW or pasteuriZed milk is cultured, clotted by 
acid, rennet or both. The resulting curd is then cut and 
shaped into the desired form With or Without pressing. Fresh 
cheeses such as cottage cheese or cream cheese do not 
require any further processing. Other varieties of cheese are, 
hoWever, subsequently cured or ripened to obtain a desired 
consistency, ?avor and aroma. These characteristics are 
produced by a partial breakdoWn of milk proteins and fat by 
the action of microbial, milk and rennet enZymes. 
The acid produced during the manufacture of cheese 
results from the fermentation of the milk sugar, lactose. 
Generally, this fermentation is initiated by the addition to the 
milk of a culture of specially selected acid bacteria. KnoWn 
as a starter culture, many different types of lactic acid 
bacteria may be utiliZed for this purpose. The acid produc 
tion in the cheese curd resulting from the activity of the 
starter culture advantageously functions to retard the groWth 
of other bacteria that Would otherwise cause undesirable 
fermentations in the cheese. Further, the acid production also 
favors the expulsion of the Whey and the fusion of the curd 
particles. 
The lactic acid starter cultures utiliZed in cheese making 
may comprise single or mixed strains of bacteria. All, 
hoWever, must convert milk sugar in the curd into lactic acid 
Within a reasonable time if a high quality cheese is to result. 
Several factors may, hoWever, prevent this conversion. Of 
these factors, the most important is bacteriophage attack. 
Speci?cally, cheese production loss due to phage attacks on 
lactic culture is the number one problem faced by the dairy 
products industry today. 
Bacteriophages or phages, are viruses that attack a lactic 
acid bacteria cell, commandeer the biosynthetic or repro 
ductive machinery of the cell, produce neW phages and in 
the process lyse the bacteria cell. Phages are prevalent in 
cheese making facilities. They may contaminate the milk in 
a number of Ways including through use of infected starter 
cultures or through contact With phage-carrying dust par 
ticles. 
Phages effectively sloW doWn or totally inhibit the activity 
of the starter culture. As a result, the milk fermentation 
medium is often insuf?ciently soured and insuf?cient acid is 
produced to retard the groWth of undesirable bacteria that 
cause undesired fermentation products. Hence, the cheese 
spoils resulting in an undesired consistency, ?avor, and/or 
aroma. 
It is knoWn that phage multiplication is in?uenced by 
temperature, pH and calcium content of the medium among 
other factors. While phage outbreaks can be at least partially 
controlled by rigorous hygienic handling of starters, by 
culture rotation and/or by culturing starters in calcium 









proliferation and attacks on starter cultures are desired. 
ToWard this end, hoWever, it should be appreciated that 
attempts to isolate phage-resistant strains have generally not 
met With success. A need is therefore identi?ed for an 
improved method of controlling bacteriophage attacks on 
lactic acid bacteria utiliZed in the cheese making process. 
SUMMARY OF THE INVENTION 
Accordingly, it is a primary object of the present invention 
to provide an improved method of reducing or preventing 
bacteriophage attack on bacteria used in the cheese making 
process, overcoming the above-described limitations and 
disadvantages of the prior art. 
An additional object of the present invention is to provide 
a simple and effective method of controlling bacteriophage 
attacks on lactic acid bacteria used in the cheese making 
process Wherein the bacteria are protected against attack. 
Speci?cally, blocker peptides are produced and collected. 
These blocker peptides attach to sites on the cheese making 
bacteria and subsequently prevent attachment of bacterioph 
ages so that the bacteria may continue to function normally, 
fermenting milk sugar and producing the desired curd more 
effectively and ef?ciently. As a direct consequence of the 
resulting faster processing time, if any bacteriophage infec 
tion does take place it is limited and localiZed and, therefore, 
does not have a substantial adverse effect on the resulting 
cheese product. Superior quality and greater productivity is 
therefore insured. 
Still another object of the present invention is to provide 
a related method of making cheese With bacteriophage 
resistant cheese making bacteria as Well as a relatively high 
quality cheese With more uniform consistency, ?avor and 
aroma. 
Additional objects, advantages and other novel features of 
the invention Will be set forth in part in the description that 
folloWs and in part Will become apparent to those skilled in 
the art upon examination of the folloWing or may be learned 
With the practice of the invention. The objects and advan 
tages of the invention may be realiZed and obtained by 
means of the instrumentalities and combinations particularly 
pointed out in the appended claims. 
To achieve the foregoing and other objects, and in accor 
dance With the purposes of the present invention as 
described herein, a method is provided for controlling (e.g. 
reducing or preventing) bacteriophage attack on bacteria 
such as lactic acid bacteria starter culture used in a cheese 
making process. The method includes the steps of treating a 
blocker peptide precursor selected from a group consisting 
of a source of immunoglobulins, bacteriophages, bacte 
riophage parts or mixtures thereof With a protease enZyme 
that hydrolyZes the blocker peptide precursor. The method 
also includes the collecting of the blocker peptides produced 
by the hydrolysis of the blocker peptide precursor and the 
formulating and heat treating of a starter media With the 
blocker peptides. Finally, the method includes the additional 
steps of groWing bulk cultures of bacteria used in the cheese 
making process in a peptide containing starter media and 
adding the bacteria groWn in the peptide containing starter 
media to a fermentation medium for producing cheese. 
More speci?cally describing the invention, the source for 
immunoglobulins may include raW Whey, dried Whey, Whey 
protein isolates, non-fat dried milk, blood serum protein 
isolates, puri?ed immune protein preparations and mixtures 
thereof. Preferably, the bacteriophage parts includes spikes, 
tail ?bers, ?laments and mixtures thereof. Also, the enZyme 
used in the present method is preferably selected from a 
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group consisting of papain, bromelain, ?cin and mixtures 
thereof. Of these, papain appears to be the most preferred 
enzyme. 
In accordance With a further aspect of the present 
invention, a method of making cheese With bacteriophage 
resistant cheese making bacteria is provided. In addition to 
the above steps, this method includes the cutting of the curd. 
Speci?cally, the curd is cut at a selected time in an effort to 
increase cheese yield and maximiZe the result and quality of 
the cheese. For example, the curd may be cut in accordance 
With the method set forth in my co-pending US. Pat. No. 
5,172,193 entitled “Method of Predicting Cut-Time of Milk 
Coagulum in Cheese-Making Process”. Further, the method 
may include the additional step of curing the curd to provide 
a cheese of desired consistency, ?avor and aroma. Any 
knoWn method of curing may be utiliZed to produce a cheese 
of desired qualities. Cheeses produced in accordance With 
the present method are also the subject of the present 
invention. 
Still other objects of the present invention Will become 
apparent to those skilled in this art from the folloWing 
description Wherein there is shoWn and described a preferred 
embodiment of this invention, simply by Way of illustration 
of one of the modes best suited to carry out the invention. As 
it Will be realiZed, the invention is capable of other different 
embodiments and its several details are capable of modi? 
cation in various, obvious aspects all Without departing from 
the invention. Accordingly, the draWings and descriptions 
Will be regarded as illustrative in nature and not as restric 
tive. 
BRIEF DESCRIPTION OF THE DRAWING 
The accompanying draWing incorporated in and forming 
a part of the speci?cation, illustrates several aspects of the 
present invention and together With the description serves to 
explain the principles of the invention. In the draWing: 
FIG. 1 is a graphical representation comparing lactic acid 
bacteria starter culture as a control With starter culture 
inoculated in accordance With the teachings of the present 
invention in various concentrations folloWed by phage intro 
duction at various concentrations; 
FIG. 2 is a graphical representation of the effect of peptide 
blocker concentration on the lag time before cell lyses 
begins folloWing introduction of bacteriophage; 
FIG. 3 is a graphical representation of the effect of peptide 
blocker concentration on the rate of lysing of lactic acid 
bacteria cells. 
Reference Will noW be made in detail to the present 
preferred embodiment of the invention, an example of Which 
is illustrated in the accompanying draWing. 
DETAILED DESCRIPTION OF THE 
INVENTION 
A method of controlling bacteriophage attack on bacteria 
used in a cheese making process Will noW be described in 
detail. The method includes the initial step of treating a 
blocker peptide precursor selected from a group consisting 
of a source of immunoglobulins, bacteriophages, bacte 
riophage parts and mixtures thereof With a protease enZyme 
that hydrolyses the blocker peptide precursor. Preferably, the 
source of immunoglobulins includes raW Whey, dried Whey, 
Whey protein isolates, non-fat dried milk, blood serum 
protein isolates, puri?ed immune protein preparations and 
mixtures thereof. It should be appreciated, hoWever, that this 
list is presented only for purposes of illustration and the 









The bacteriophage parts are preferably spikes, tail ?bers, 
?laments and mixtures thereof. Still more speci?cally, the 
bacteriophages and parts thereof utiliZed as blocker peptide 
precursors are of a type or strain to Which cheese making 
bacteria are sensitive. Generally, such cheese making bac 
teria include lactic acid bacteria such as available, for 
example, from CHR. Hansen’s of Mississauga, Ontario 
including but not limited to mesophilic homofermentative, 
thermophilic and mesophilic aromatic cultures as marketed 
under the trademarks PHAGE CONTROL, DVS, PHAGE 
HARDENED, REDI-SET, SCO, ST/LH/LB, HR/HC, 
ITALIANO, CH-N, PS, DSG, CAF and FLORA DANICA. 
Of course, lactic acid starter cultures are available from 
other sources including, for example, Rhone-Poulenc (e.g. 
various Lactococcus, lactis ssp., Lactococcus lactic ssp. 
cremoris, and Streptococcus thermophilous cultures identi 
?ed by culture numbers: D11-LF, D15, D30-LF, D37, D40 
LF, D50, D52-LF, D62, D71, D75, D84, D107, D115, D120, 
D175, D180-LF, D205, D210, D220, D230, D250, D265, 
D270, D275, D509-LF, L12, M30, M32, M46, M49, M56, 
M58, M59, EZ 10, EZ 15, EZ 20, EZ 25, LF2, LF3, DPL 
569, DPL 571, DPL 572, DPL 573, DPL 574, DPL 575, DPL 
576, DPL 577, DPL 578, DPL 579, MA011, MA014, 
MA016, MA019, EZ100, EZ200, EZ300; various thermo 
philic cultures including Streptococcus thermophilous, Lac 
tobacillus delbruekeii ssp. bulaaricus, Lactobacillus helveti 
cus and Lactobacillus delbruekeii ssp. lactis cultures With 
the folloWing culture numbers: C90, C100, C110, C120, 
C130, C150, C160, C180, C260, C280, C300, C310, C320, 
C330, C340, R110, R130, R150, R160, RX160, R170, 
R180, R190, TC120, TC234, TC246, TC257, TR160, TEX 
1, TEX 2, TEX 3, CR5, CR12, CR14, LBST, KCR5, TA052, 
TA054, TA060, TA061, TA062, LH100, LB120; as Well as 
additional mixed and pure cultures including the above 
species alone or in combination With Lactococcus lactis ssp. 
lactis biovar diacetylactis, Leuconostoc mesenteroides ssp. 
cremoris, Bi?dobacterium, Lactobacillus acidophilus, Lac 
tococcus lactis ssp. lactis, Lactobacillus casei, 
Propionibacterium, Freudenrecheii ssp. shermanii, Bi?a'o 
bacterium infantis, Bi?dobacterium longum including cul 
ture numbers: 801—805, 811—815, 831—835, 851—855, 
901—905, 911—915, 921—925, 951—953, 201—205, VT3, OS, 
LD, FCS24, FLD, FMQ3, FOS, FRI, FVT3, Y604, Y605, 
Y610, Y611, Y612, Y613, Y617, Y650, Y651, Y653, ABY 
2C, THY35, THY42, THY95, CAF, JVI, BC1, BC2, MD 
series, MM series, LC-20, FB302, FB304, PS31, TC120, 
TC234, LC, NCFM, NCFM, BBI, 403 AC, 410 BBI, 411 
BBL. The enZyme utiliZed to hydrolyZe the blocker peptide 
precursor may be selected from a group of protease enZymes 
including, for example, papain, bromelain, ?cin and mix 
tures thereof. Preferably, papain is utiliZed. Papain cleaves 
the immunoglobulin IgG and IgM blocker peptide precur 
sors at a most advantageous location to provide phage 
blocking activity. For best results, the concentration of 
blocker peptide precursor to enZyme should be maintained 
betWeen 0.2—50.0 grams per 100 lbs of precursor (at a 
concentration of approximately 5% solids) and more pref 
erably should be maintained at about 1 gram per 100 lbs of 
precursor (at a concentration of approximately 5% solids). 
More particularly, the production of the blocker peptides 
may be completed in accordance With ultra?ltering and 
dia?ltering techniques. Preferably, the blocker peptide pre 
cursor being treated With the enZyme is ultra?ltered through 
a polysulfone membrane cellulose or other membrane hav 
ing a molecular Weight cut-off of less than 20,000 Daltons. 
The permeate, that is, the material passing through the 
membrane, comprises peptides having a molecular Weight of 
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less than 10,000—20,000 Daltons, depending on the siZe of 
the membrane utilized in ?ltering. 
As the blocker peptide permeate is collected, an appro 
priate dilutant (eg Water, Whey or pasteurized skim milk) 
may be added to the source of immunoglobulins treated With 
the enZyme. This is done volume-for-volume so that the 
original volume of the blocker peptide precursor and 
enZyme (i.e., the retentate) is substantially maintained at a 
given level. This serves to maintain substrate concentrations 
and reduce product inhibition. The enZymatic treatment of 
the blocker peptide precursor is completed at any appropri 
ate temperature Where enZymatic inactivation does not 
occur. HoWever, temperatures just beloW the enZyme’s point 
of denaturation are most efficient. Accordingly, for papain, 
the enZymatic treatment is completed betWeen 30—50° C. 
and most preferably at approximately 40° C. Further, the 
enZymatic treatment is completed for a relatively extended 
period of time of at least tWo hours. This alloWs the enZyme 
to hydrolyZe signi?cant portions of the blocker peptide 
precursor. Of course, a greater concentration of enzyme may 
be used to shorten the processing time. 
After collecting the blocker peptides produced by the 
hydrolysis of the blocker peptide precursor, the blocker 
peptides may be concentrated if desired utiliZing, for 
example, reverse osmosis or evaporation in accordance With 
procedures Well knoWn in the art. These peptides may then 
be dried by using freeZe drying, spray drying, or vacuum 
drying techniques also Well knoWn to those in the art. These 
dried blocker peptides may then be subsequently formulated 
into useable preparations or lactic groWth media by, for 
example, mixing With appropriate carriers such as 
phosphate, citrate, buffers or Water and groWth stimulants 
such as yeast extract. 
Next is the step of inoculating a groWth or starter media 
With the blocker peptides. Such starter media for cheese 
making bacteria are Well knoWn in the art. Preferably, the 
starter media is formulated With blocker peptides having a 
concentration of about 5.0% dry Weight When using a starter 
media in poWered form. The starter media and peptide 
blocker premix is then mixed With distilled Water. For best 
effect, the concentration of blocker in the groWth or starter 
media after mixing With distilled Water should at least be 0.5 
mg/ml. 
Lactic starter media containing blocker peptides are then 
heat treated using traditional methods knoWn by those 
skilled in the art at temperatures such as 85° C. for 45 
minutes, to destroy any microorganisms that may have 
contaminated the starter media. The starter media is then 
cooled for temperatures that supports the lactic culture of 
choice. 
Next is the groWing of.bulk cultures of bacteria used in 
the cheese making process in this inoculated starter media. 
This is folloWed by adding the bacteria groWn in the 
inoculated starter media to a fermentation media (eg raW or 
pasteuriZed milk) for producing cheese. 
Advantageously, the blocker peptides bind and block 
binding sites/determinates on the bacteria thereby providing 
a competitive inhibition to subsequent phage attack. 
Accordingly, the cheese making bacteria continue to func 
tion normally fermenting the milk sugar and producing the 
desired curd more effectively and ef?ciently. In fact, fer 
mentation processing time may be signi?cantly reduced and, 
accordingly, (While unlikely) if any bacteriophage infection 
does take place it is limited and localiZed. Thus, such a 
bacteriophage infection does not have any substantial 














Accordingly, it should be appreciated that the present inven 
tion both increases productivity While also ensuring a more 
uniform and higher quality end product. 
In accordance With still another aspect of the present 
invention, a method of making cheese With bacteriophage 
resistant cheese making bacteria further includes a step of 
cutting the resulting curd that is formed in the fermentation 
media by the activity of the cheese making bacteria. The 
cutting of the curd may be accomplished in accordance With 
any appropriate means knoWn in the art at a time that may, 
for example, be identi?ed by utiliZing any of the methods set 
forth in my co-pending US. Pat. No. 5,172,193. 
Further, the cheese making method may also include the 
step of curing the curd to provide a cheese of desired 
consistency, ?avor and aroma. As is knoWn in the art, curing 
consists of a series of biological and chemical changes that 
are affected by the moisture content, acidity, texture, shape, 
siZe, and microorganisms in the cheese. The chemical 
changes may include the breakdoWn of fats to fatty acids, 
proteins to amino acids, and lactose to various products 
including lactic, acidic and propionic acids, diacetyl, as Well 
as carbon dioxide. Some of the ?avorful products of the 
curing process include various volatile fatty acids, alcohols, 
esters, ketones, peptides, and amino acids produced during 
this process. 
The advantageous effect of the method of the present 
invention produced by the peptide blockers on phage pro 
liferation in a lactic acid bacteria culture is best demon 
strated With reference to FIGS. 1—3. The phage concentra 
tion at the point of inoculation Was 8.4><105/ml. Peptide 
blocker concentration includes approximately 72% lactose. 
As clearly demonstrated in FIG. 1, peptide blockers can 
inhibit phage attachment to lactic cells (Lactococcus lactis 
ssp. lactis WWA4). FIG. 2 graphically demonstrates the 
resulting increase in lag times (that is, the time from phage 
addition to point Where rate of lysis exceeds cultured 
groWth). FIG. 3 graphically demonstrates the resulting 
decrease in the lysis rate. Together, this data clearly suggests 
that the antigenic binding sites on the surface of the lactic 
bacteria cells are not competitively bound until a concen 
tration of 0.5 mg/ml of blocker is added to the groWth media. 
At blocker concentrations greater than 0.5 mg/ml, a com 
petitive inhibition is observed betWeen the phage and the 
blockers for the antigenic sites. Advantageously, When uti 
liZing the blocker peptides in the present method, cheese vat 
phage proliferation is inhibited suf?ciently so that the curd 
may be completely coagulated for cutting before phage 
attack becomes a signi?cant problem adversely effecting 
quality of the cheese product. 
The folloWing examples are presented to further illustrate 
the invention, but are not to be considered as limited thereto. 
EXAMPLE 1 
Blocker peptides Were prepared from a rennet Whey 
blocker peptide precursor. Speci?cally, 5000 ml of rennet 
Whey Were treated With 500 mg of crude papain (Sigma 
Chemical Co., St. Louis, Mo.) While being ultra?ltered and 
dia?ltered using a holloW ?ber membrane (Supelco, 
Bellefonte, Pa.) With a molecular Weight cut-off of 10,000 
Daltons. The process ran for tWo hours at 40° C. The 
permeate Was collected and freeZe dried air dried for sub 
sequent use as blocker peptides in controlling bacteriophage 
attack on bacteria in accordance With the present method. 
EXAMPLE 2 
Blocker peptides are prepared from a rennet Whey blocker 
peptide precursor. Speci?cally, 5000 ml of rennet Whey is 
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treated With 500 mg of bromelain (ICN Biomedicals, Inc., 
Iruine, Calif.) While being ultra?ltered and dia?ltered using 
a hollow ?ber membrane (Supelco, Bellefonte, Pa.) With a 
molecular Weight cut-off of 10,000 Daltons. The process 
runs for tWo hours at 40° C. The permeate is collected and 
freeZe dried or air dried for subsequent use as blocker 
peptides in controlling bacteriophage attack on bacteria in 
accordance With the present method. 
EXAMPLE 3 
Blocker peptides are prepared from a rennet Whey blocker 
peptide precursor. Speci?cally, 5000 ml of rennet Whey is 
treated With 100 mg of ?cin (ICN Biomedicals, Inc., Irvine, 
Calif.) While being ultra?ltered and dia?ltered using a hol 
loW ?ber membrane (Supelco, Bellefonte, Pa.) With a 
molecular Weight cut-off of 10,000 Daltons. The process 
runs for tWo hours at 40° C. The permeate is collected and 
freeZe dried or air dried for subsequent use as blocker 
peptides in controlling bacteriophage attack on bacteria in 
accordance With the present method. 
EXAMPLE 4 
Lactic bacteria (Lactococcus lactis ssp. lactis WWA4, 
1><109 cfu/ml) is added to groWth or starter media M17. 
After 90 minutes, bacteriophage c2 (2><107 pfu/ml) (i.e. a 
phage speci?c to the lactic bacteria groWn in the starter 
media) is added to the culture. After approximately 120—150 
minutes, the phage lyse all bacteria cells. The medium 
containing the phage is then disrupted using a tissue 
homogeniZer, blender, sonicator or other disruptive device. 
The disrupted suspension of phage parts including spikes, 
tail ?bers and ?laments is then hydrolyzed With one or more 
protease enZymes such as papain, bromelain or ?cin. EnZy 
matic hydrolysis takes place While the suspension is being 
ultra?ltered and dia?ltered using a holloW ?ber membrane 
With a molecular Weight cut-off of, for example, 10,000 
Daltons. The process runs for 2 hours at approximately 40° 
C. The permeate is collected and may be freeZe dried air 
dried by any appropriate method knoWn in the art. The 
permeate may then be subsequently utiliZed in the method of 
the present invention to control bacteriophage attack on 
bacteria used in the cheese making process. 
EXAMPLE 5 
Lactococcus lactis ssp. lactis C2 bulk starter (incubated at 
26° C. for 16 hours in M17 broth) Was used to inoculate 
(2%) media consisting of M17 broth With CaCl2 (3 samples) 
and M17 broth With CaCl2 plus fractionated Whey peptide 
blocker (4%) (2 samples). Phage c2 (2><107 pfu/ml) Was 
added (1%) to four incubating cultures (26 C) (tWo With 
blocker, tWo Without) at 30 min or 60 min after culture 
inoculation. Cell groWth Was observed (A?oonm) immedi 
ately after culture inoculation and at 20 min intervals for 5 
hours. Blocker-containing media inhibited bacteriophage 
proliferation and decreased rate of cell lysis. Media With 
blocker extended cell groWth time by 29.8 and 21.5 min for 
cultures inoculated With bacteriophage at 30 and 60 min, 
respectively. Rate of lysis generally increased With cell 
numbers. HoWever, 55% and 52.5% reductions in rate of cell 
lysis Were observed When cells Were groWn in blocker 
containing media inoculated With bacteriophage at 30 and 60 
min, respectively. 
EXAMPLE 6 
Peptides, fractionated from hydrolyZed Whey, and col 














?ber Romicon ultra?ltration membrane, Were used to pre 
pare a phage inhibitory medium. Bulk starter Was prepared 
from M17 broth inoculated (4%) With WWA-SCO166-4 
single strain lactic culture. M17 broth (heat treated at 85 C 
for 45 min and cooled to 24 C) containing Whey peptide 
blockers (0, 0.025, 0.05, 0.075, and 0.1 g/mL) Was inocu 
lated With WWA-SCO 166-4 bulk starter and incubated for 
6.0 hours. WWA4-phage Were added to the groWing culture 
(103 pfu/mL) after 90 min of incubation. Cell groWth Was 
monitored spectrometrically (A?oomn) at 10 min intervals. As 
peptide blocker concentration increased the time to bacterial 
cell lysis increased and the rate of bacterial lysis decreased. 
Time from phage introduction to maximum absorbance 
increased linearly from 85 min (0 g/ml blocker) to 147.5 min 
(0.1 g/mL blocker). Slope of bacterial lysis did not change 
until blocker concentration exceeded 0.05 g/ml. A linear 
decrease in lysis rate Was observed for blocker concentra 
tions of 0.05 to 0.1 g/mL, suggesting that antigenic sites on 
the surface of lactic cells must be saturated before the 
attachment of phage could be competitively inhibited. In 
other experiments Where phage concentration varied from 
101 to 103 pfu/mL, time to maximum absorbance decreased 
as phage concentration increased. HoWever, the time differ 
ential betWeen media With and Without blockers increased 
linearly With phage concentration suggesting that blocker 
concentration Was most effective When lactic cell numbers 
Were loWest. 
What is claimed is: 
1. Amethod of controlling bacteriophage attack on cheese 
making bacteria used in a cheese making process, compris 
mg: 
treating a blocker peptide precursor selected from a group 
consisting of a source of immunoglobulins, bacterioph 
ages to Which cheese making bacteria are sensitive, 
bacteriophage parts to Which cheese making bacteria 
are sensitive and mixtures thereof With a protease 
enZyme that hydrolyZes the blocker peptide precursor; 
collecting blocker peptides produced by hydrolysis of the 
blocker peptide precursor; 
formulating a starter mediate With the blocker peptides 
and heat treating the formulated starter media; 
groWing bulk cultures of cheese making bacteria used in 
the cheese making process in the formulated starter 
media; and 
adding cheese making bacteria groWn in the formulated 
starter media to a fermentation medium for producing 
cheese. 
2. The method set forth in claim 1, Wherein said source of 
immunoglobulins includes raW Whey, dried Whey, Whey 
protein isolates, non-fat dried milk, blood serum protein 
isolates, puri?ed immune protein preparations and mixtures 
thereof. 
3. The method set forth in claim 1, Wherein said bacte 
riophage parts include spikes, tail ?bers, ?laments and 
mixtures thereof. 
4. The method set forth in claim 1, Wherein said bacte 
riophage parts include spikes, tail ?bers, ?laments and 
mixtures thereof. 
5. The method set forth in claim 1, Wherein said enZyme 
is selected from a group consisting of papain, bromelain, 
?cin and mixtures thereof. 
6. The method set forth in claim 2, Wherein said enZyme 
is selected from a group consisting of papain, bromelain, 
?cin and mixtures thereof. 
7. The method set forth in claim 3, Wherein said enZyme 
is selected from a group consisting of papain, bromelain, 
?cin and mixtures thereof. 
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8. The method set forth in claim 4, wherein said enzyme 
is selected from a group consisting of papain, bromelain, 
?cin and mixtures thereof. 
9. A method of making cheese With bacteriophage resis 
tant cheese making bacteria, comprising: 
formulating a starter media With peptides that block 
bacteriophage attachment sites on the cheese making 
bacteria; 
groWing bulk cultures of the cheese making bacteria in the 
formulated starter media; 
adding the cheese making bacteria groWn in the formu 
lated starter media to a fermentation media for produc 
ing cheese Whereby a curd is formed; and 
cutting the curd. 
10. The method set forth in claim 9, including a further 
step of curing the curd to provide a cheese of desired 
consistency, ?avor and aroma. 
11. The method set forth in claim 10, further including: 
treating a blocker peptide precursor selected from a group 
consisting of a source of immunoglobulins, 
bacteriophages, bacteriophage parts and mixtures 
thereof With a protease enZyme that hydrolyzes the 




collecting blocker peptides produced by hydrolysis of the 
blocker peptide precursor, said collected blocker pep 
tides being utiliZed to inoculate the starter media. 
12. The method set forth in claim 11, Wherein said source 
of immunoglobulins include raW Whey, dried Whey, Whey 
protein isolates, non-fat dried milk, blood serum protein 
isolates, puri?ed immune protein preparations and mixtures 
thereof. 
13. The method set forth in claim 12, Wherein said 
bacteriophage parts include spikes, tail ?bers, ?laments and 
mixtures thereof. 
14. The method set forth in claim 10, Wherein said 
bacteriophage parts include spikes, tail ?bers, ?laments and 
mixtures thereof. 
15. The method set forth in claim 10, Wherein said 
enZyme is selected from a group consisting of papain, 
bromelain, ?cin and mixtures thereof. 
16. The method set forth in claim 12, Wherein said 
enZyme is selected from a group consisting of papain, 
bromelain, ?cin and mixtures thereof. 
17. The method set forth in claim 14, Wherein said 
enZyme is selected from a group consisting of papain, 
bromelain, ?cin and mixtures thereof. 
* * * * * 
